Meta Biomed Co., Ltd. announced that it expects to receive KRW 24 billion in funding from Mirae Asset Securities Co., Ltd., Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., KB-Suseong No. 1 New Technology Business Investment Association and another investor
March 06, 2024
Share
Meta Biomed Co., Ltd. announced a private placement to issue Series 8 Bearer-Type, Non-Coupon-Bearing, Non-Guaranteed Private Placement Convertible Bonds for the gross proceeds of KRW 24,000,000,000 on March 7, 2024.The transaction will include participation from new investors KB Securities Co., Ltd. ( In the position of trustee of Fund 1 ) for KRW 1,250,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 2 ) for KRW 1,250,000,000, NH Investment & Securities Co., Ltd. ( In the position of trustee of Fund 3 ) for KRW 1,000,000,000, NH Investment & Securities Co., Ltd. ( In the position of trustee of Fund 4 ) for KRW 800,000,000, Samsung Securities Co., Ltd. ( In the position of trustee of Fund 5 ) for KRW 200,000,000, NH Investment & Securities Co., Ltd. ( In the position of trustee of Fund 6 ) for KRW 500,000,000, NH Investment & Securities Co., Ltd. ( In the position of trustee of Fund 7 ) for KRW 1,500,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 8 ) for KRW 2,000,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 9 ) for KRW 1,500,000,000, Samsung Securities Co., Ltd. ( In the position of trustee of Fund 10 ) for KRW 500,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 11 ) for KRW 2,000,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 12 ) for KRW 700,000,000, NH Investment & Securities Co., Ltd. ( In the position of trustee of Fund 13 ) for KRW 500,000,000, NH Investment & Securities Co., Ltd. ( In the position of trustee of Fund 14 ) for KRW 800,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 15 ) for KRW 800,000,000, KB Securities Co., Ltd.
( In the position of trustee of Fund 16 ) for KRW 500,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 17 ) for KRW 700,000,000, Mirae Asset Securities Co., Ltd. ( In the position of trustee of Fund 18 ) for KRW 500,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 19 ) for KRW 100,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 20 ) for KRW 400,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 21 ) for KRW 500,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 22 ) for KRW 800,000,000, KB Securities Co., Ltd.( In the position of trustee of Fund 23 ) for KRW 200,000,000, Samsung Securities Co., Ltd. ( In the position of trustee of Fund 24 ) for KRW 500,000,000, Shinhan Investment & Securities Co., Ltd. ( In the position of trustee of Fund 25 ) for KRW 500,000,000, KB Securities Co., Ltd. ( In the position of trustee of Fund 26 ) for KRW 500,000,000, JB-Rhinos Mezzanine New Technology Business Fund for KRW 2,000,000,000 and KB-Suseong No. 1 New Technology Business Investment Association for KRW 1,500,000,000. The bonds are 100% convertible into 5,005,213 shares at a fixed conversion price of KRW 4,795 from March 11, 2025 to February 11, 2029. The bonds bear zero coupon rate and zero maturity rate and matures on March 11, 2024. The transaction has been approved by the shareholders of the company and is expected to close on March 11, 2024. The securities are restricted to a hold period.
Meta Biomed Co., Ltd. is a Korea-based company engaged in the manufacture of medical materials and equipment for biotechnology and dental areas. The Company mainly operates its business through three divisions: suture material division, dental division and bone material division. Its suture material division provides suture materials, such as polyglycolic acid (PGA) synthetic absorbable braids, polyglycolic acid-co-lactic acid (PGLA) absorbable braids, polydioxanone (PDO) synthetic absorbable monofilaments, polyglycolide-co-epsilon-caprolactone (PGCL) synthetic absorbable monofilaments and others. Its dental division provides dental materials and equipment, such as gutta percha cordless obturation systems, electronic apex locators, taper points, root canal sealers, root canal filling materials and others. Its bone materials division provides bone graft substitutes. It also distributes dental-related products.
Meta Biomed Co., Ltd. announced that it expects to receive KRW 24 billion in funding from Mirae Asset Securities Co., Ltd., Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., KB-Suseong No. 1 New Technology Business Investment Association and another investor